The total return over the past 12 months is -42.91% vs. +16.94% for the S&P 500. So far it's up -40.39% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (42.91%) | (28.52%) | (32.98%) | (20.93%) | (17.79%) | N/A |
| Total Return CAGR | (42.91%) | (28.52%) | (32.98%) | (20.93%) | (17.79%) | N/A |
| Revenue CAGR | (36.71%) | (7.08%) | (10.62%) | (3.15%) | +5.46% | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Standard BioTools Inc. (LAB)
| Year | Start price | End price | LAB Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $1.28 | $0.76 | (40.39%) | +14.51% | (54.90%) |
| 2025 | $1.75 | $1.28 | (26.86%) | +17.72% | (44.58%) |
| 2024 | $2.21 | $1.75 | (20.81%) | +24.89% | (45.70%) |
| 2023 | $1.17 | $2.21 | +88.89% | +26.19% | +62.70% |
| 2022 | $3.92 | $1.17 | (70.15%) | (18.17%) | (51.98%) |
| 2021 | $6.00 | $3.92 | (34.67%) | +28.74% | (63.41%) |
| 2020 | $3.48 | $6.00 | +72.41% | +18.37% | +54.04% |
| 2019 | $8.62 | $3.48 | (59.63%) | +31.22% | (90.85%) |
| 2018 | $5.89 | $8.62 | +46.35% | (4.56%) | +50.91% |
| 2017 | $7.28 | $5.89 | (19.09%) | +21.70% | (40.79%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
